Inventor · disambiguated record
Rene Bernards
Also filed as: BERNARDS RENE · BERNARDS RENé
17 granted patents·20 pending applications·501 citations·filing 1995–2023
93Inventor score
Files withPROLIFIX LTD8STICHTING HET NEDERLANDS KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS5BERNARDS RENE4NETHERLANDS CANCER INST2STICHTING HET NL KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS2
Top patents by PatentIndex Score
37 records- 0196US7514209B2Diagnosis and prognosis of breast cancer patientsROSETTA INPHARMATICS LLC·Filed 2002·Granted Apr 7, 2009·139 cites·44 claims
- 0295US7171311B2Methods of assigning treatment to breast cancer patientsNETHERLANDS CANCER INST·Filed 2003·Granted Jan 30, 2007·289 cites·33 claims
- 0384US7863001B2Diagnosis and prognosis of breast cancer patientsNETHERLANDS CANCER INST·Filed 2008·Granted Jan 4, 2011·7 cites·9 claims
- 0476US8969544B2Combined use of PRAME inhibitors and HDAC inhibitorsBERNARDS RENé·Filed 2011·Granted Mar 3, 2015·6 cites·2 claims
- 0574US6699475B1Recombinant pox virus for immunization against tumor-associated antigensTHERION BIOLOG CORP·Filed 1995·Granted Mar 2, 2004·41 cites·7 claims
- 0673US9909185B2Diagnosis and prognosis of breast cancer patientsTHE NETHERLANDS CANCER INST·Filed 2012·Granted Mar 6, 2018·2 cites·16 claims
- 0764US7928081B2Combined use of PRAME inhibitors and HDAC inhibitorsBERNARDS RENE·Filed 2005·Granted Apr 19, 2011·1 cites·7 claims
- 0863US2025228834A1Pharmaceutical composition for the treatment of colon and lung cancerHEPAREGENIX GMBH·Filed 2023·Application pending·0 cites
- 0961US2018305768A1Diagnosis and prognosis of breast cancer patientsTHE NETHERLANDS CANCER INST·Filed 2018·Application pending·0 cites
- 1061US2023310418A1Compositions and methods for treating cancer or preventing, inhibiting or reducing risk of metastasis of a cancerLIXTE BIOTECHNOLOGY INC·Filed 2023·Application pending·0 cites
- 1160US10398696B2Combinations for treatment of cancerSTICHTING HET NEDERLANDS KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS·Filed 2014·Granted Sep 3, 2019·0 cites·5 claims
- 1257US2024382499A1Inducers of senescence, in combination with a selective death receptor 5 (dr5) agonist, for use in a method of treating cancerSTICHTING HET NEDERLANDS KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS·Filed 2022·Application pending·0 cites
- 1356US2010297624A1Involvement of Lipid Kinase, and Signal Transduction Pathway Comprising Said Lipid Kinase, in Resistance to HER2-Targeting TherapySTICHTING NL KANKER INST·Filed 2008·Application pending·0 cites
- 1454US2016186269A1Novel translocations in lung cancerSTICHTING HET NL KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS·Filed 2014·Application pending·0 cites
- 1552US2022280499A1Novel drug combinations for treatment of a carcinomaSTICHTING HET NEDERLANDS KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS·Filed 2020·Application pending·0 cites
- 1651US6350572B1Interaction between cyclin D1 and steroid receptor coactivators and users thereof in assaysPROLIFIX LTD·Filed 1999·Granted Feb 26, 2002·6 cites·5 claims
- 1750US2013302321A1Methods and Means for Typing a Sample Comprising Cancer Cells Based on Oncogenic Signal Transduction PathwaysSUN TIAN·Filed 2011·Application pending·0 cites
- 1849US2011301048A1Diagnosis and prognosis of breast cancer patientsDAI HONGYUE·Filed 2010·Application pending·0 cites
- 1948US2003059794A1Adenoviral library assay for E2F regulatory genes and methods and compositions for screening compoundsFiled 2002·Application pending·0 cites
- 2047US2017292162A1Method and Means for Typing a Sample Comprising Cancer Cells Based on Oncogenic Signal Transduction PathwaysAGENDIA N V·Filed 2017·Application pending·0 cites
- 2146US2003166167A1Adenoviral library assay for E2F regulatory genes and methods and compositions for screening compoundsFiled 2002·Application pending·0 cites
- 2246US2016319367A1Means and methods for typing a breast cancer patient and assigning therapy based on the typingStichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis·Filed 2014·Application pending·0 cites
- 2345US7012128B2Interaction between cyclin D1 and steroid receptor co-activators and uses thereof in assaysTOPOTARGET UK LTD·Filed 2001·Granted Mar 14, 2006·0 cites·5 claims
- 2445US6368809B1E2F ubiquitination domain, and assays for inhibitors and enhancers of E2F ubiquitinationPROLIFIX LTD·Filed 1997·Granted Apr 9, 2002·4 cites·15 claims
- 2544US2015275306A1Methods and means for predicting resistance to anti-cancer treatmentSTICHTING HET NL KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS·Filed 2013·Application pending·0 cites
- 2642US2014296248A1Methods and compositions for predicting resistance to anticancer treatmentBERNARDS RENE·Filed 2012·Application pending·0 cites
- 2741US2018051346A1Methods and means for subtyping invasive lobular breast cancerSTICHTING HET NEDERLANDS KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS·Filed 2016·Application pending·0 cites
- 2839US10864179B2Histone deacetylase inhibitors for the use in the treatment of drug resistant melanomaSTICHTING HET NEDERLANDS KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS·Filed 2016·Granted Dec 15, 2020·0 cites·7 claims
- 2939US2006105344A1Modulation of deubiquitinase family membersBERNARDS RENE·Filed 2004·Application pending·0 cites
- 3038US2003022260A1Transcription factor - E2F-5PROLIFIX LTD·Filed 2002·Application pending·0 cites
- 3137US2014287931A1Methods and compositions for predicting resistance to anticancer treatmentBERNARDS RENE·Filed 2012·Application pending·0 cites
- 3235US6045999ATranscription factor E2F-4PROLIFIX LTD·Filed 1995·Granted Apr 4, 2000·2 cites·14 claims
- 3334US2005181360A1Assay for cell cycle modulators based on the modulation of cyclin d1 degradation in response to ionising radiationFiled 2001·Application pending·0 cites
- 3433US6303335B1Transcription factor E2F-4PROLIFIX LTD·Filed 1999·Granted Oct 16, 2001·4 cites·11 claims
- 3529US5985283AAdenovirus E1A-Associated protein BS69, inhibitor of E1A-transactivationPROLIFIX LTD·Filed 1996·Granted Nov 16, 1999·0 cites·12 claims
- 3622US6448376B1Transcription factor-E2F-5PROLIFIX LTD·Filed 1995·Granted Sep 10, 2002·0 cites·11 claims
- 3721US6033843AInteraction of cyclin D1 and estrogen receptor and its use in assaysPROLIFIX LTD·Filed 1997·Granted Mar 7, 2000·0 cites·9 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →